scispace - formally typeset
F

F. Boitier

Researcher at Paris Descartes University

Publications -  26
Citations -  1554

F. Boitier is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Melanoma & Germline mutation. The author has an hindex of 12, co-authored 26 publications receiving 1429 citations. Previous affiliations of F. Boitier include University of Paris & Institut Gustave Roussy.

Papers
More filters
Journal ArticleDOI

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Corine Bertolotto, +98 more
- 01 Dec 2011 - 
TL;DR: A germline missense substitution in MITF (Mi-E318K) is identified that occurred at a significantly higher frequency in genetically enriched patients affected with melanoma, RCC or both cancers, when compared with controls and provides insights into the link between SUMOylation, transcription and cancer.
Journal ArticleDOI

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

Alisa M. Goldstein, +99 more
- 15 Oct 2006 - 
TL;DR: This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available and there was little evidence for an association between CDKN2A mutations and NST, but there was a marginally significant association between NST and ARF.
Journal ArticleDOI

Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis.

TL;DR: The tight association of MCV with MCC, the clonal pattern ofMCV integration, and the expression of the viral oncoproteins strongly support a causative role for MCV in the tumour process.
Journal ArticleDOI

Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy.

TL;DR: It is shown that melanomas during pregnancy frequently harbor fetal cells that have an endothelial phenotype, which is needed to assess whether the fetal contribution to lymphangiogenesis may alter the prognosis of the maternal tumor.